Сравнение
Survodutide vs. Tirzepatide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
2179963-22-7
2023788-19-2
Молекулярная масса
4727 g/mol
4813 g/mol
Период полувыведения
168 h
116 h
Последовательность
modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteYXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSМеханизм действия
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
4
из них на людях
4
4
Зафиксированные эффекты
3
4
Открытые противоречия
1
1
Задокументированные нежелательные явления
2
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Survodutide and Tirzepatide?
- Survodutide is classified as "Метаболизм", while Tirzepatide is classified as "Метаболизм". Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Survodutide or Tirzepatide?
- The highest available evidence level is "РКИ на людях" for Survodutide and "РКИ на людях" for Tirzepatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Survodutide and Tirzepatide in Germany and the United States?
- Германия: Survodutide — Не одобрено, Tirzepatide — Рецептурный. США: Survodutide — Не одобрено, Tirzepatide — Рецептурный. These are factual summaries with source and review date on the individual pages.